Aims: To evaluate the efficacy of oesophageal cooling in the prevention of oesophageal injury in patients undergoing atrial fibrillation (AF) catheter ablation. Methods and results: Comprehensive search of MEDLINE, EMBASE, and Cochrane databases through April 2022 for randomized controlled trials (RCTs) evaluating the role of oesophageal cooling compared with control in the prevention of oesophageal injury during AF catheter ablation. The study primary outcome was the incidence of any oesophageal injury. The meta-analysis included 4 RCTs with a total of 294 patients. There was no difference in the incidence of any oesophageal injury between oesophageal cooling and control [15% vs. 19%; relative risk (RR) 0.86; 95% confidence interval (CI) 0.31–2.41]. Compared with control, oesophageal cooling showed lower risk of severe oesophageal injury (1.5% vs. 9%; RR 0.21; 95% CI 0.05–0.80). There were no significant differences among the two groups in mild to moderate oesophageal injury (13.6% vs. 12.1%; RR 1.09; 95% CI 0.28–4.23), procedure duration [standardized mean difference (SMD) −0.03; 95% CI −0.36–0.30], posterior wall radiofrequency (RF) time (SMD 0.27; 95% CI −0.04–0.58), total RF time (SMD −0.50; 95% CI −1.15–0.16), acute reconnection incidence (RR 0.93; 95% CI 0.02–36.34), and ablation index (SMD 0.16; 95% CI −0.33–0.66). Conclusion: Among patients undergoing AF catheter ablation, oesophageal cooling did not reduce the overall risk of any oesophageal injury compared with control. Oesophageal cooling might shift the severity of oesophageal injuries to less severe injuries. Further studies should evaluate the long-term effects after oesophageal cooling during AF catheter ablation.
26 July 2023 in Catheterization and Cardiovascular Interventions
Randomized clinical trials (RCTs) evaluating the role of intravenous (IV) iron administration in patients with heart failure (HF) and iron deficiency (ID) have yielded inconsistent results. Electronic search of MEDLINE, EMBASE and OVID databases was performed until November 2022 for RCTs that evaluated the role of IV iron administration in patients with HF and ID. The main study outcomes were the composite of HF hospitalization or cardiovascular mortality, and individual outcome of HF hospitalization. Summary estimates were evaluated using random effects model. The final analysis included 12 RCTs with 3,492 patients (1,831 patients in the IV iron group and 1,661 patients in the control group). The mean follow-up was 8.3 months. IV iron was associated with a lower incidence in the composite of HF hospitalization or cardiovascular mortality (31.9% vs. 45.3%; relative risk [RR] 0.72; 95% confidence interval [CI] 0.59–0.88) and individual outcome of HF hospitalization (28.4% vs. 42.2; RR 0.69; 95% CI 0.57–0.85). There was no significant difference between both groups in cardiovascular mortality (RR 0.88; 95% CI 0.75–1.04) and all-cause mortality (RR 0.95; 95% CI 0.83–1.09). IV iron was associated with lower New York Heart Association class and higher left ventricular ejection fraction (LVEF). Meta-regression analyses showed no effect modification for the main outcomes based on age, hemoglobin level, ferritin level or LVEF. Among patients with HF and ID, IV iron administration was associated with reduction in the composite of HF hospitalization or cardiovascular mortality and driven by a reduction in HF hospitalization.
15 July 2025 in Journal of the American Heart Association
Background: Older adult patients have been underrepresented in the pivotal trials comparing an invasive versus conservative management for non–ST‐segment–elevation myocardial infarction (NSTEMI). Methods: We performed an electronic search of MEDLINE, Embase, and Cochrane databases through September 2024 for randomized controlled trials comparing invasive versus conservative management of NSTEMI in patients aged ≥70 years. Results: The final analysis included 7 randomized controlled trials with 2997 patients. The weighted mean follow‐up time was 47.1 months, and the mean age was 82.6 years. There was no significant difference in all‐cause mortality between an invasive versus a conservative management approach (27.9% versus 26.6%; risk ratio [RR], 1.05 [95% CI, 0.94–1.18]; I2 =0%). There was a statistically nonsignificant trend for fewer major adverse cardiac events in the invasive group (28.3% versus 33.4%; RR, 0.82 [95% CI, 0.68–1.00]; P =0.05, I2 =58%). An invasive approach was associated with a lower risk of recurrent myocardial infarction (RR, 0.76 [95% CI, 0.60–0.97]) and ischemia‐driven revascularization (RR, 0.29 [95% CI, 0.21–0.40]) without an increase in major bleeding (RR, 1.31 [95% CI, 0.86–1.97]) compared with a conservative approach. There were no significant differences between both approaches in cardiovascular mortality, acute cerebrovascular events, or length of hospital stay. Conclusions: Among older adult patients with NSTEMI, there was no significant difference in survival between an invasive or a conservative approach. An invasive approach was associated with a lower risk of recurrent myocardial infarction and ischemia‐driven revascularization without an increase in the risk of major bleeding. The findings should help with informed decision‐making among older adult patients with NSTEMI.